Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of Hepatitis C Cirrhotic Patients With Directly Acting Antivirals: A Multicenter Study.

Infectious disorders drug targets - 1 Jan 2021

Elfert Asem Ahmed, Abd-Elsalam Sherief, Abo-Ali Lobna, Eldemerdash Taher, Abou-Saif Sabry, Elsabagh Hala Mostafa, Ebeid Abla, Badawi Rehab

Abstract excerpt

BACKGROUND: With the introduction of sofosbuvir-based regimens, high cure rates and decreased duration has been achieved. Several studies showed variances in SVR rates between different genotypes, with lower rates of SVR among cirrhotic patients. The aim of our study was to assess the safety and effectiveness of sofosbuvir-based antiviral regimens for the treatment of HCVinfected Egyptian cirrhotic patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Liver Cirrhosis

Share to Treatment Outcome

Source

Identifiers

PMID: 33076813
DOI: 10.2174/1871526520666201019122205

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of Hepatitis C Cirrhotic Patients With Directly Acting Antivirals: A Multicenter Study.PMID 33076813Read ↗

Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.Semantic proximity Read ↗

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infectionSemantic proximity Read ↗

Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.Semantic proximity Read ↗

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.Semantic proximity Read ↗

Chronic Hepatitis C and comorbidities: real-world study to evaluate impact in outcomes after treatment with sofosbuvir-based regimensSemantic proximity Read ↗

Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.Semantic proximity Read ↗

Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.Semantic proximity Read ↗

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.Semantic proximity Read ↗

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.Semantic proximity Read ↗

Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.Semantic proximity Read ↗

Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.